A novel budesonide orodispersible tablet with a special esophageal-targeting can induce complete clinical, endoscopic and histologic remission in active Eosinophilic Esophagitis: Results from a post-hoc analysis of the randomized, double-blind, placebo-controlled EOS-1 trial

(1) Coopertion of Internal Medicine Center for Digestive Diseases,Hamburg,Germany

(2) Technische Universität München,München,Germany

(3) Swiss EoE Research Network,Olten,Switzerland

(4) Klinikum Bayreuth Abt. Pathology,Bayreuth,Germany

(5) Dr. Falk Pharma GmbH,Freiburg,Germany

(6) Hospital General de Tomelloso Dept. of Digestive Health,Tomelloso,Spain

This item was part of the Oesophageal, Gastric and Duodenal Disorders I (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019